Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

about

A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis.Current developments in pharmacogenomics of multiple sclerosis.Glatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.

P2860

Q33742905-AA287442-505A-4BE1-A00B-662D5F7CB622 Q38239501-9D5845AE-1636-4D65-84F6-B1BCBD19B167 Q38449394-8999160D-865A-4F1D-A2C5-08F8DA60B37F

P2860

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

Item

http://www.wikidata.org/entity/Q51089837

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@en

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@nl

type

Item

label

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@en

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@nl

prefLabel

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@en

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@nl

P1476

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

@en

P2093

Alexander V Favorov

http://www.w3.org/2001/XMLSchema#string

Alexey N Boyko

http://www.w3.org/2001/XMLSchema#string

Dmitrijs Lvovs

http://www.w3.org/2001/XMLSchema#string

Ekaterina Yu Tsareva

http://www.w3.org/2001/XMLSchema#string

Olga G Kulakova

http://www.w3.org/2001/XMLSchema#string

P2860

New and emerging disease modifying therapies for multiple sclerosis

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

The mechanism of action of interferon-β in relapsing multiple sclerosis

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action

Beta-interferon for multiple sclerosis.

Classical immunomodulatory therapy in multiple sclerosis: how it acts, how it works.

A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.

Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.

P304

679-685

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.14.26

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Olga Favorova

P577

2014-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

262075839

http://www.w3.org/2001/XMLSchema#string

P698

24798724

http://www.w3.org/2001/XMLSchema#string

P921

multiple sclerosis

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

about

P2860

P2860

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921